TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07278479: Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Sponsor: Molecular Partners AG · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 138 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$12,016,620

Rescue Site Savings

+$7,932,540

Unlock Full NCT07278479 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07278479 Rescue Dossier →